bluuebunny/crossref_metadata_2025_split huggingface dataset:
1-LB: Diurnal Regulation of Pancreatic Beta-Cell Proliferation following Massive Ablation
Authors: PETRENKO VOLODYMYR , STOLOVICH-RAIN MIRI , VANDEREYCKEN BART , CHERA SIMONA , DOR YUVAL , DIBNER CHARNA 
Published: June 2020

Pancreatic islet cellular oscillators have been recently demonstrated to play a critical role in regulating glucose homeostasis in physiological conditions. However, little is known about changes of molecular clockwork upon islet dysfunction, and its role in beta (b)-cell regeneration. We aimed to assess diurnal regulation of b-cell proliferation and circadian transcriptome of alpha (a)- and b-cells following massive b-cell ablation in rtTA/TET-DTA mouse model. Diurnal proliferation of remnant b-cells was assessed by injecting bromodeoxyuridine (BrdU) before sacrificing in several time-points across 24 h. The role of functional islet oscillators in b-cell regeneration was studies in clock deficient mice. Our data suggest that both absolute levels and diurnal profiles of blood glucose, insulin and glucagon are altered following b-cell ablation. Temporal RNAseq analyses suggest massive changes in b-cell temporal transcriptome landscape, with modest alterations in a-cell transcriptional regulation. Complimentary differential RNAseq analysis of b-cells between intact islets and after ablation showed altered expression of genes involved in hormone secretory pathway, and activation of transcripts responsible for cell proliferation. In line with the circadian rhythmicity of cell-cycle related transcripts, the incorporation of BrdU by residual b-cells exhibited circadian rhythmicity. Moreover, we show that also in young pups, b-cell proliferation follows diurnal pattern. Importantly, the arrhythmic Bmal1 KO mice failed to regenerate b-cells after ablation.
To conclude, loss of b-cell mass in rtTA/TET-DTA mice affects gene transcription in residual b-cells, but not in a-cells, while the temporal transcriptome profile is perturbed in both cell types, paralleled with impaired daily secretion of insulin and glucagon. Noteworthy, the key component of molecular clock Bmal1 is required for proper regeneration and functional recovery after massive b-cell ablation.

Disclosure
V. Petrenko: None. M. Stolovich-Rain: None. B. Vandereycken: None. S. Chera: None. Y. Dor: None. C. Dibner: None.

Funding
Swiss National Science Foundation (31003A_166700/1, 310030_184708/1)
1002-P: The ROTO Track Device Improves Rotation of Insulin Injections in T1DM: A Proof-of-Concept Study
Authors: KLARSKOV CARINA K. , HAMID YASMIN H. , TJALK-BØGGILD RASMUS T. , TARNOW LISE , KRISTENSEN PETER L. 
Published: June 2020

Lipohypertrophy (LH), a common side effect of insulin therapy, is caused by repetitively injecting insulin into the same location.
When insulin is injected into LH lesions, the absorption of insulin may be erratic and unpredictable, which can lead to unexpected hyperglycemia and hypoglycemia and increased blood glucose variability.
To improve injection techniques and avoid LH, a new medical device, ROTO Track® which automatically guides the person with diabetes to rotate the abdominal insulin injections was tested.
The hypothesis is that the device can reduce the number of insulin injections in the same subcutaneous area as compared with non-aided standard insulin injection techniques in people with T1DM.
Methods: In this proof-of-concept cross-over study, baseline data about injection site in the abdominal region was collected blinded for one week with a non-guiding version of the device and compared to 12 weeks of device guidance in 35 people with T1DM. The device registered injection time and location on the abdomen. Based on this a "rotation score", the primary endpoint, was calculated. Secondary end points included number and size of LH, glycemic variability and HbA1c. LH sizes were documented by drawing on a wound care grid after palpation of the skin. Interstitial glucose was measured with a continuous glucose monitor and the coefficient of variation, CV was calculated.
Results: The rotation score improved significantly from a baseline mean of 40.2% to 49.9% after one week (CI: 2.2% - 17.2%, p=0.012) and improved further after 12 weeks to 52.2% (p&lt;0.001).
After 12 weeks, LH was reduced both in mean size from 11.9 (+/- 9.5) cm2 to 8.2 (+/- 9.7) cm2 (p=0.041) and numbers (p=0.039) and the CV of interstitial glucose was reduced from 38.6 to 35.1 (p=0.009).
There were no changes in mean interstitial glucose, HbA1c or hypoglycemic events after 12 weeks.
Conclusion: This proof-of-concept study indicates that the device is safe, improves rotation, reduces LH and reduces glycemic variability.

Disclosure
C.K. Klarskov: None. Y.H. Hamid: None. R.T. Tjalk-Bøggild: Board Member; Self; ROTO Health ApS. Employee; Self; ROTO Health ApS. L. Tarnow: None. P.L. Kristensen: None.

Funding
Innovation Fund Denmark (8063-00049B); Nordic Healthcare Technology
1004-P: Oral Insulin (ORMD-0801) Effects on Glucose Parameters in Uncontrolled T2DM on OADs
Authors: ELDOR ROY , FLEMING G. ALEXANDER , NEUTEL JOEL , HOMER KENNETH E. , KIDRON MIRIAM , ROSENSTOCK JULIO 
Published: June 2020

ORMD-0801 is a novel oral human insulin formulation which can potentially improve acceptance and adherence, as well as glycemic control by increasing hepatic insulin exposure, without increasing hypoglycemia risk. This randomized, placebo-controlled, multi-center, phase 2b 12-week study, in 273 T2DM subjects, on metformin ±1-2 oral antidiabetic drugs (OADs), including sulfonylurea, compared placebo vs. 32 mg ORMD-0801 capsules administered once daily (QD) at bedtime, or two (BID) or three (TID) times daily at bedtime, and 30-40 min before breakfast/lunch. Blinded continuous glucose monitoring (CGM) was performed during a two-week run-in period and over the last two weeks of treatment. HbA1c levels improved from baseline for all active treatment regimens (Table). Glucose AUC improved from baseline following QD and BID treatment. Hypoglycemia rates were low and relatively similar to the placebo arm, and body weight was unchanged in all treatment arms. Frequency of drug-related adverse events was similar across treatment groups.
In conclusion, ORMD-0801 elicited clinically significant HbA1c reductions among T2DM patients inadequately controlled on standard therapies, without increasing hypoglycemia rates, or inducing severe or serious adverse effects or significant weight gain.

Disclosure
R. Eldor: Advisory Panel; Self; Oramed. Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Medtronic, Merck Sharp & Dohme Corp., Novo Nordisk Inc., Sanofi. Stock/Shareholder; Self; Oramed. G. Fleming: Consultant; Self; ADOCIA, Biocon, Caladrius Biosciences, Inc., Dance Biopharm Holdings, Inc., Diasome Pharmaceuticals, Inc., Intarcia Therapeutics, MannKind Corporation, NuSirt Biopharma, Inc., Oramed Pharmaceuticals, Sanofi, Tolerion, Inc. J. Neutel: None. K.E. Homer: None. M. Kidron: Employee; Self; Oramed Pharmaceuticals. Stock/Shareholder; Self; Oramed Pharmaceuticals. J. Rosenstock: Research Support; Self; AstraZeneca, Bristol-Myers Squibb, Genentech, Inc., GlaxoSmithKline plc., Lexicon Pharmaceuticals, Inc., Oramed Pharmaceuticals, PegBio Co., Ltd., Pfizer Inc., REMD Biotherapeutics. Other Relationship; Self; Applied Therapeutics, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Intarcia Therapeutics, Janssen Pharmaceuticals, Inc., Novo Nordisk Inc., Sanofi.
1005-P: Comparison of Hypoglycemia Safety between U-100 Human Regular Insulin and Rapid-Acting Insulin Delivered By V-Go Wearable Insulin Delivery in Type 2 Diabetes
Authors: MORA PABLO F. , SUTTON DAVID R. , GORE ASHWINI , BALIGA BANTWAL , GOLDFADEN REBECCA F. , NIKKEL CARLA C. , SINK JOHN H. , ADAMS-HUET BEVERLEY A. 
Published: June 2020

Hypoglycemia was evaluated in a 14-week multi-center randomized, parallel, non-inferiority study comparing the efficacy and safety of Rapid Acting Insulin (RAI) versus Human Regular Insulin (HRI) when delivered by V-Go. Glucose lowering agents were to remain stable unless hypoglycemia warranted removal and down-titration of insulin was recommended if glucose levels were consistently lower than target range. Patients were instructed to self-monitor blood glucose (SMBG) daily and perform 7-point SMBG profiles within 3 days of each study visit. Hypoglycemia was defined as: Level 1: ≤70 mg/dl; Level 2: ≤54 mg/dl; and Level 3: severe cognitive impairment requiring external assistance for recovery. The intent to treat population (ITT) consisted of 136 patients randomized to continue treatment with RAI (n=67) or switch to HRI (n=69). Percentages of hypoglycaemia events were similar between groups when comparing pre to post-randomization and the between group difference was not significant. Post-randomization hypoglycemic event rate/person week decreased in both groups compared to pre-randomization. No level 3 events were reported in either group. The incident rate ratio (IRR) was not significant at any level. This study demonstrates the risk of hypoglycemia is not increased when using HRI compared to RAI in V-Go in a T2D population.

Disclosure
P.F. Mora: Speaker’s Bureau; Self; Dexcom, Inc., Insulet Corporation, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk Inc., Sanofi US, Valeritas, Inc. D.R. Sutton: Employee; Spouse/Partner; Valeritas, Inc. Speaker’s Bureau; Self; Amarin Corporation, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk A/S, Valeritas, Inc. A. Gore: Advisory Panel; Spouse/Partner; Janssen Pharmaceuticals, Inc. Consultant; Spouse/Partner; Janssen Pharmaceuticals, Inc. Consultant; Self; Novo Nordisk Inc. Speaker’s Bureau; Spouse/Partner; Janssen Pharmaceuticals, Inc. Speaker’s Bureau; Self; Janssen Pharmaceuticals, Inc., Merck & Co., Inc. B. Baliga: Speaker’s Bureau; Self; Amarin Corporation, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Lilly Diabetes, Novo Nordisk Inc., Senseonics, Valeritas, Inc. R.F. Goldfaden: None. C.C. Nikkel: Employee; Self; Valeritas, Inc. Stock/Shareholder; Self; Valeritas, Inc. J.H. Sink: Employee; Self; Valeritas, Inc. B.A. Adams-Huet: Consultant; Self; Valeritas, Inc.

Funding
Valeritas, Inc.
1009-P: Glucose Outcomes in Adult Patients with Type 1 Diabetes on a Hybrid Closed-Loop System: A Single Center Study
Authors: KIM STEPHANIE , BEDRICH MARLENE , KOBASIC KRYSTAL , CROSS HAZEL , FISHER LAWRENCE , MASHARANI UMESH 
Published: June 2020

Objectives: Medtronic’s 670G insulin pump was the first to incorporate automatic basal insulin delivery based on input from CGM data, a setting called Smart Guard Automode. We assessed glycemic control (A1c) in 52 patients with T1DM who used the Medtronic 670G hybrid closed loop system and started Automode from 2017 to 2019. Our goal was to determine the effects of Automode use on A1c over time. The average age was 46.4 ± 12.3 years, 53.4% male and 78.8% Caucasian. The average age at diagnosis was 19.1 ± 13.5 years and duration was 27.3 ± 14.6 years. Diabetic complications were present in 55.8% patients.
Methods: Patients were divided into two groups depending on whether their A1c was above or below the mean baseline A1c for the cohort; 26 patients had A1c ≤7.6% (mean 6.9 ± 0.4, range 6.2 to 7.6, Group 1) and 26 had A1c &gt;7.6 (mean 8.3 ± 0.5, range 7.7-9.3, Group 2). Follow-up A1c was assessed a mean of 17.1 ± 7.3 months after beginning Automode.
Results: 1. The average A1c of the 52 patients prior to initiating Automode was 7.6 ± 0.8 (range 6.2-9.3). Follow-up A1c for the cohort was 7.5 ± 0.67 (range 6.3-9). 2. At follow-up, Group 1’s mean A1c remained about the same at 7.1 ± 0.5 (range 6.3-8.4) whereas Group 2’s mean A1c was reduced to 7.8 ± 0.6 (range 6.9-9). Females displayed greater A1c improvement (-0.2 ± 0.6, range -1.2-9) than males (-0.1 ± 0.6, range -1.4-0.7) and those with complications showed greater A1c improvement (-0.2 ± 0.5, range -1.2-0.7) than those without (-0.1 ± 0.6, range -1.4-0.9). Additionally, the 27 patients with duration of diabetes ≥25 years showed greater improvement in A1c (-0.2 ± 0.5, range -1.2-0.7) than those with duration &lt;25 years (-0.06 ± 0.6, range -1.4-0.9).
Conclusion: Patients with worse baseline glucose control (mean 8.3 ± 0.5) had improved A1c using the hybrid closed loop system compared to patients with higher A1c (mean 6.9 ± 0.4). We also observed a nonsignificant trend towards improvements in females, patients with complications and longer duration of diabetes.

Disclosure
S. Kim: None. M. Bedrich: None. K. Kobasic: Stock/Shareholder; Self; Abbott Laboratories, AbbVie Inc., General Electric, Medtronic. H. Cross: None. L. Fisher: None. U. Masharani: None.
1010-P: Personalized Automated Determination of Insulin Pump Settings for People with Type 1 Diabetes Switching from MDI to Pump Therapy and Vice Versa
Authors: NIMRI REVITAL , MULLER IDO , ATLAS ERAN , PHILLIP MOSHE 
Published: June 2020

Transition from MDI to pump therapy may be beneficial to a wide range of people with diabetes such as young children, newly diagnosed, switching to closed-loop therapy and more. At times the reverse transition is needed, such as during pump malfunction, or when a "pump holiday" is required. The Switch Advisor is a decision support system developed to ease, personalize and optimize the transition between MDI to pump therapy or vice versa.
Methods: The Switch Advisor was evaluated for safety in two feasibility, one arm studies. Each study included 4 weeks of data collection while participants used their regular treatment modality, then participants switched to the second mode of therapy based on algorithm recommendations. CGM related matrices were compared between the data collection period and 2 weeks after switching to the second mode of therapy. Primary outcomes were time in hypoglycemia &lt; 54 mg/dl and time in range of 70-180 mg/dl.
Results: 11 participants [aged 22.8y (3.7), A1c 7.3% (0.8), and 56.5 (7.7) mmol/mol, mean (SD)] completed the first study of, transition from pump to MDI therapy. 12 participants [aged 12.7 (4.3), A1c 8.4 (0.9) and 68 (9.8) mmol/mol] completed the second study of, transition from MDI to pump therapy. Mean percent (SD) TIR 70-180 mg/dl was 62% (13) and time &lt; 54 mg/dl was 3% (2) during pump therapy and 58% (9) and 4% (5) after switching to MDI, respectively (P=N.S). TIR 70-180 mg/dl was 50% (15) and time &lt; 54 mg/dl was 3% (3) during MDI therapy and 63% (15) and 2% (3) after switching to pump therapy (P=0.01, P=N.S, respectively). TDD of insulin was 59 (24) U during pump therapy and 54 (26) U after switch to MDI (N=9) and 30 (18) U during MDI therapy and 33(14) U after switching to pump therapy (N=10). No serious adverse events occurred during both studies.
Conclusions: An automated algorithm to determine initial pump therapy settings and MDI was found to be feasible and safe. RCT studies are needed to confirm the results of these feasibility studies.

Disclosure
R. Nimri: Employee; Self; DreaMed Diabetes. Stock/Shareholder; Self; DreaMed Diabetes. I. Muller: Board Member; Self; DreaMed Diabetes. E. Atlas: Board Member; Self; DreaMed Diabetes. Employee; Self; DreaMed Diabetes. Stock/Shareholder; Self; DreaMed Diabetes. M. Phillip: Consultant; Self; Qulab Medical, RSP Systems A/S. Research Support; Self; JDRF. Stock/Shareholder; Self; NG Solutions Ltd, Nutriteen Professionals Ltd. Other Relationship; Self; AstraZeneca, Dexcom, Inc., DreaMed Diabetes, Eli Lilly and Company, Insulet Corporation, Medtronic, Novo Nordisk A/S, OPKO Health, Inc., Pfizer Inc., Sanofi-Aventis.

Funding
JDRF (1-SRA-2017-422-M-B)
1014-P: Unannounced Meals at Home with the Medtronic Advanced Hybrid Closed-Loop
Authors: TIROSH AMIR , SHALIT ROY , HIRSH MAYA LARON , COHEN OHAD , KURTZ NATALIE , ROY ANIRBAN , GROSMAN BENYAMIN 
Published: June 2020

Background and Aims: Advanced Hybrid closed loop (AHCL) algorithm combines automated basal rate with additional enhancement when a rise in glucose level is detected. This study assessed the effectiveness and safety of AHCL with unannounced meals.
Methods: Fourteen participants were using Medtronic AHCL system at home for a mean of 72.6 days. Each participant spent 4 days in a protected free-living environment while consuming pre-defined meals consisting of up to 80 grams of carbohydrates each day. On day 5, participants initiated a 3-months unannounced meal phase at their homes with the instruction to announce only meals containing over 80 grams.
Results: Fourteen subjects with T1DM (10 males, mean age 44.3±3.9 years) and baseline HgbA1C% of 6.75± 1.2 were enrolled. Patients spent 97±3% of time in Auto-Mode, with mean SG of 157.8±19.2. Mean %time in range70-180was 67.6±12.8, %time &lt;70 mg/dL of 2±1.7%, and % time &lt;54 mg/dL of 0.4±0.5%. Table 1 summarizes the glycemic indices.
Conclusion: Medtronic AHCL system is designed for best performance with meal announcement. Nevertheless, when meals containing ≤ 80 gram of carbohydrates are consumed without meal announcement, the system can provide safe glycemic control with about 67.6% of TIR.

Disclosure
A. Tirosh: Advisory Panel; Self; Novo Nordisk Inc., Sanofi. R. Shalit: Research Support; Self; Medtronic. M. Laron Hirsh: None. O. Cohen: Employee; Self; Medtronic. N. Kurtz: Employee; Self; Medtronic. A. Roy: Employee; Self; Medtronic. B. Grosman: Employee; Self; Medtronic.

Funding
Medtronic
1016-P: Treatment Preferences and Quality of Life in Brazilian T1DM
Authors: COELHO RAQUEL C.L. , PAGANO ADRIANA S. , SOARES ALEIDA N. , REIS JANICE S. 
Published: June 2020

We carried out an observational study to analyze if the quality of life of T1DM patients is affected by different insulin treatment systems. The study involved 113 T1DM patients from a public diabetes center, mean age 32.61(±12.59) years, 46% male treated with MDI or CSII. The Insulin System Rating Questionnaire (IDSRQ) was validated in Brazilian Portuguese (Table 1) and was self-completed by the subjects during a routine visit. Multiple comparison analysis (Table 2) showed that CSII had a significant effect versus syringe and versus pen for treatment satisfaction and clinical efficacy domains. CSII was associated with a higher treatment satisfaction and patient’s perception of better clinical efficacy than MDI.

Disclosure
R.C.L. Coelho: None. A.S. Pagano: None. A.N. Soares: None. J.S. Reis: None.
1018-P: Ultra-Rapid Lispro (URLi) Showed Greater Reduction in Postprandial Glucose (PPG) vs. Humalog in Children, Adolescents, and Adult Patients with Type 1 Diabetes (T1D)
Authors: ARONSON RONNIE , LINNEBJERG HELLE , LEOHR JENNIFER , LABELL ELIZABETH S. , COUTANT DAVID E. , ZHANG QIANYI , DANNE THOMAS , POLLOM ROBYN K. 
Published: June 2020

URLi is a novel insulin lispro formulation that was developed to more closely match physiological insulin secretion. This 2-site, randomized, 2-period crossover, double-blind study evaluated the pharmacokinetics and glucodynamics during a liquid test meal, after a single 0.2 U/kg SC dose of URLi or Humalog in 13 children, 14 adolescents, 15 adults with T1D. Onset of insulin appearance was faster with URLi vs. Humalog in children (1.1 vs. 6.5 min; p=0.0002), adolescents (1.9 vs. 6.4 min; p=0.001), and adults (0.9 vs. 4.8 min; p=0.004). Early exposure (AUC0-15min) was greater with URLi vs. Humalog: 7-fold (p&lt;0.0001) in children, 4 fold (p=0.0003) in adolescents, 5-fold (p&lt;0.0001) in adults; late exposure (AUC3-7h) was reduced by 58% (p&lt;0.0001) in children, 40% (p=0.013) in adolescents, 37% (p=0.021) in adults. Total exposure was similar in URLi and Humalog. At 1h, URLi reduced PPG by 42 mg/dL (p=0.008) in children, 19 mg/dL (p=0.195) in adolescents, 34 mg/dL (p=0.018) in adults, vs. Humalog. At 2h, URLi reduced the PPG by 32 mg/dL (p=0.11) in children, 39 mg/dL (p=0.051) in adolescents and was not statistically different in adults, vs. Humalog. URLi was well tolerated in all age groups.
In summary, URLi accelerated insulin lispro absorption, reduced late exposure and early PPG following a test meal vs. Humalog in children, adolescents, and adults with T1D.

Disclosure
R. Aronson: None. H. Linnebjerg: Employee; Self; Eli Lilly and Company. Stock/Shareholder; Self; Eli Lilly and Company. J. Leohr: None. E.S. LaBell: Employee; Self; Eli Lilly and Company. Stock/Shareholder; Self; Eli Lilly and Company, Johnson & Johnson, Novartis AG. D.E. Coutant: Employee; Self; Eli Lilly and Company. Employee; Spouse/Partner; Eli Lilly and Company. Q. Zhang: Employee; Self; Eli Lilly and Company. Stock/Shareholder; Self; Eli Lilly and Company. T. Danne: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Medtronic, Novo Nordisk A/S, Sanofi. R.K. Pollom: Employee; Self; Eli Lilly and Company. Stock/Shareholder; Self; Eli Lilly and Company.

Funding
Eli Lilly and Company
1019-P: Variability of 501 Inhaled Insulin Absorption and Action
Authors: ZIJLSTRA ERIC , ANDERSEN GRIT , PLUM-MOERSCHEL LEONA , RHODES MELISSA , PATTON RYAN , BUECHE BLAINE , KUO MEI-CHANG , LE TRUC H. , STEDMAN BENJAMIN J. , PATTON JOHN S. 
Published: June 2020

501 inhaled insulin (INH) is a novel liquid formulation of human insulin for inhalation with faster onset of action than s.c. insulin lispro (LIS). This randomized, replicated cross-over trial investigated the variability of INH vs. LIS during 10-hour glucose clamps in non-smoking subjects with T1D. Fourteen subjects (age [mean±SD] 32.5±7.9 years, BMI 26.5±2.1 kg/m2, HbA1c 7.5±0.8 %) received 2 single doses of 92.2 IU INH via the Afina inhaler (n=13 completing subjects) and 2 injections of an equivalent 12 U LIS dose (n=12). The inhalations were performed by the subjects after a brief training on the correct inhalation technique; injections were given by trained staff. Repeated dosing of INH by the same subject resulted in reproducible insulin absorption and insulin action, with lower or similar variability vs. LIS (Table 1). The response to INH between subjects was more variable than for LIS. The 13.8±8.1% mean relative biopotency of INH was consistent with previous findings. INH was well tolerated, adverse events (8 with INH, 13 with LIS) were mild to moderate in severity. No cough and no acute changes in spirometry were observed with any inhalation.
In conclusion, the intra-individual response to self-administration of 501 inhaled insulin is as reproducible as that of s.c. insulin lispro injected by experienced staff. This is a clinically meaningful outcome and enables individual dose titration of 501 insulin in future treatment.

Disclosure
E. Zijlstra: Employee; Self; Profil. Speaker’s Bureau; Self; Aerami Therapeutics, Eli Lilly and Company, Novo Nordisk A/S. G. Andersen: Employee; Self; Profil Institute for Clinical Research. L. Plum-Moerschel: Other Relationship; Self; Eli Lilly and Company, Novo Nordisk A/S. M. Rhodes: None. R. Patton: None. B. Bueche: None. M. Kuo: None. T.H. Le: None. B.J. Stedman: None. J.S. Patton: Board Member; Self; Dance Biopharm Holdings, Inc.